GRAPHIC PACKAGING HOLDING CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GRAPHIC PACKAGING HOLDING CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.62B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $8.81B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $9.43B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $9.44B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $7.16B | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $1.65B | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $1.70B | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $1.61B | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | $1.60B | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $1.52B | Feb 16, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.58B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $8.78B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $9.38B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $9.41B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $7.13B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.54B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $6.14B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $6.01B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $4.38B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $4.28B | Feb 13, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $261.80M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $255.50M | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $262.10M | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | $320.80M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $272.30M | Feb 16, 2021 |
| FY2020 | Sep 30, 2019 | $266.40M | Feb 16, 2021 |
| FY2020 | Jun 30, 2019 | $287.80M | Feb 16, 2021 |
| FY2020 | Mar 31, 2019 | $266.10M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $232.70M | Feb 11, 2020 |
| FY2019 | Sep 30, 2018 | $258.30M | Feb 11, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $444.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $658.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $723.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $522.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $204.00M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $64.20M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $63.70M | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $52.10M | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | ($12.70M) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $33.00M | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $804.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.12B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.17B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $906.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $407.00M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $130.40M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $119.10M | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $114.80M | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | $160.00M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $133.00M | Feb 16, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $17.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $16.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $14.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $10.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $10.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $9.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $8.70M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $14.40M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $14.90M | Feb 13, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $704.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $774.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $805.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $774.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $528.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $513.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $512.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $472.10M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $347.50M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $353.40M | Feb 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $841.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $840.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.14B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $1.09B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $609.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $825.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $666.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($373.80M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | ($192.50M) | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $74.00M | Feb 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.78B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $11.14B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $11.18B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $10.33B | Feb 21, 2024 |
| FY2023 | Dec 31, 2021 | $10.46B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $7.81B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $7.29B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $7.06B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $4.86B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $4.60B | Feb 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2012 | $10.80M | Feb 6, 2014 |
| FY2012 | Dec 31, 2011 | $14.80M | Feb 7, 2013 |
| FY2011 | Dec 31, 2010 | $3.74B | Feb 23, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.34B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.01B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $2.78B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $2.15B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.89B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.42B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.57B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.58B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $1.29B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $1.06B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.07B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.99B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $2.10B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $1.98B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.02B | Feb 21, 2024 |
| FY2021 | Jul 1, 2021 | $68.00M | Feb 22, 2022 |
| FY2022 | Dec 31, 2020 | $1.48B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.48B | Feb 22, 2022 |
| FY2020 | Aug 1, 2019 | $7.50M | Feb 16, 2021 |
| FY2020 | Dec 31, 2018 | $1.46B | Feb 16, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.61B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.03B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $469.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $66.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | ($48.00M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $56.40M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $10.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | ($56.00M) | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | ($268.00M) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $157.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $162.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $150.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $172.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $179.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $152.90M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $70.50M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $67.40M | Feb 13, 2019 |
| FY2018 | Dec 31, 2016 | $59.10M | Feb 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.43B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $5.05B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $5.22B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.10B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.68B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $3.52B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.73B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $2.83B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.25B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $2.11B | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 295.13M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 300.16M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 306.06M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | 307.12M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 307.10M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | 267.73M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 290.25M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 299.89M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | 309.72M | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | 313.53M | Feb 23, 2018 |